ASSESSMENT OF CARDIAC BIOMARKER WITH MYOCARDIAL 2D STRAIN ECHOCARDIOGRAPHY FOR EARLY DETECTION OF DOXORUBICIN INDUCED CARDIOTOXICITY IN PATIENTS UNDERGOING CHEMOTHERAPY

Abstract

BACKGROUND:

               One of the highly-effective cancer drug (doxorubicin) are used widely in the treatment of patients with HER2-positive breast cancer, ovarian cancer, leukemia etc.., and have led to important gains in survival. Cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. However, these agent carry a significant risk of cardiovascular morbidity. The present study investigates whether early alterations of myocardial strain and blood biomarker predict incident cardiotoxicity in patients  treating with doxorubicin chemotherapeutic agent.

METHODS:

             A prospective observational study was done in 30 consecutive breast cancer patients who was treated with doxorubicin. Complete clinical details of patients were taken. Blood samples were taken before and after first course of chemotherapy. hs-Trop I were measured and GLS echocardiography were performed. Pearson correlation and Spearman correlation were used to determine before and after first course of chemotherapy using doxorubicin chemotherapeutic agents.

RESULT:

            A total of 30 consecutive breast cancer patients were taken up for the study. hs TnI level increased and decline in LVEF were observed from baseline to completion of (p < 0.05) Doxorubicin cycle. A greater risk of cardiotoxicity was associated with interval changes in hs TnI and GLS.

CONCLUSION:

             Early increases in TnI and decline in LVEF levels offers additive information about the risk of cardiotoxicity in patients undergoing chemotherapy with Doxorubicin  chemotherapeutic agent.